Amy Hong

538 total citations
20 papers, 402 citations indexed

About

Amy Hong is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Amy Hong has authored 20 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Amy Hong's work include Glioma Diagnosis and Treatment (8 papers), PARP inhibition in cancer therapy (5 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Amy Hong is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), PARP inhibition in cancer therapy (5 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Amy Hong collaborates with scholars based in United States, China and Chile. Amy Hong's co-authors include Mary A. Lilly, Hari Shroff, Jason Z Morris, Ruth Lehmann, Andrew G. York, Oleg Milberg, Maria Ingaramo, Steven A. Lee-Kong, Peter Wawrzusin and George H. Patterson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Amy Hong

16 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Hong United States 7 188 146 131 76 51 20 402
Regan P. Moore United States 5 269 1.4× 208 1.4× 108 0.8× 171 2.3× 13 0.3× 6 543
Cori K. Cahoon United States 10 362 1.9× 106 0.7× 41 0.3× 79 1.0× 89 1.7× 14 475
Sara Cuylen‐Haering Germany 9 345 1.8× 77 0.5× 74 0.6× 77 1.0× 27 0.5× 10 482
Joseph Huff United States 6 204 1.1× 203 1.4× 88 0.7× 62 0.8× 25 0.5× 6 432
Anand Pratap Singh Singapore 9 198 1.1× 203 1.4× 63 0.5× 63 0.8× 12 0.2× 17 404
Jenna R. Christensen United States 10 303 1.6× 121 0.8× 53 0.4× 511 6.7× 40 0.8× 15 639
Gustavo de Medeiros Germany 11 205 1.1× 278 1.9× 177 1.4× 71 0.9× 5 0.1× 13 540
Jeroen Vangindertael Belgium 5 163 0.9× 118 0.8× 59 0.5× 127 1.7× 7 0.1× 5 350
Thorge Holm Germany 7 175 0.9× 198 1.4× 48 0.4× 59 0.8× 11 0.2× 7 381
Julian A. Eskin United States 10 506 2.7× 113 0.8× 65 0.5× 418 5.5× 49 1.0× 11 798

Countries citing papers authored by Amy Hong

Since Specialization
Citations

This map shows the geographic impact of Amy Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Hong more than expected).

Fields of papers citing papers by Amy Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Hong. The network helps show where Amy Hong may publish in the future.

Co-authorship network of co-authors of Amy Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Hong. A scholar is included among the top collaborators of Amy Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Hong. Amy Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hong, Amy, Artak Tovmasyan, An‐Chi Tien, et al.. (2025). Abstract 2513: Factors influencing participant attrition in Phase 0 hybrid clinical trials for patients with high-grade glioma. Cancer Research. 85(8_Supplement_1). 2513–2513.
2.
Sanai, Nader, Yoshie Umemura, Amy Hong, et al.. (2024). A phase 0/1 trigger trial of BDTX-1535 in patients with recurrent high-grade glioma (HGG) with EGFR alterations or fusions.. Journal of Clinical Oncology. 42(16_suppl). 2069–2069. 1 indexed citations
3.
Sanai, Nader, Yoshie Umemura, Shashvat M. Desai, et al.. (2024). JS02.5.A A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology. 26(Supplement_5). v8–v8. 1 indexed citations
4.
Sanai, Nader, Yoshie Umemura, Hualin Zhang, et al.. (2024). P18.31.A NIRAPARIB EFFICACY IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA: CLINICAL READOUT OF A PHASE 0/2 ‘TRIGGER’ TRIAL. Neuro-Oncology. 26(Supplement_5). v104–v104.
5.
Sanai, Nader, Yoshie Umemura, Jennifer K. Molloy, et al.. (2024). Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial.. Journal of Clinical Oncology. 42(16_suppl). 2002–2002. 2 indexed citations
6.
Sanai, Nader, Jennifer K. Molloy, Amy Hong, et al.. (2023). CTNI-25. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology. 25(Supplement_5). v79–v79.
7.
Mehta, Shwetal, Nader Sanai, Jennifer K. Molloy, et al.. (2023). A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology. 41(16_suppl). 2069–2069. 3 indexed citations
8.
Sanai, Nader, Jennifer K. Molloy, Amy Hong, et al.. (2023). A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.. Journal of Clinical Oncology. 41(16_suppl). 2051–2051. 1 indexed citations
9.
Sanai, Nader, Jennifer K. Molloy, William A. Knight, et al.. (2022). CTNI-14. A PHASE 0 ‘TRIGGER’ TRIAL OF NIRAPARIB IN NEWLY-DIAGNOSED GLIOBLASTOMA PATIENTS. Neuro-Oncology. 24(Supplement_7). vii73–vii73. 2 indexed citations
10.
Sanai, Nader, An‐Chi Tien, Artak Tovmasyan, et al.. (2022). CTNI-13. A FIRST-IN-HUMAN PHASE 0/1 TRIAL OF 5-AMINOLEVULINIC ACID SONODYNAMIC THERAPY (5-ALA SDT) IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 24(Supplement_7). vii72–vii73. 8 indexed citations
11.
Sanai, Nader, Yu‐Wei Chang, Jun Jiang, et al.. (2022). CTNI-44. A PHASE 0 ‘TRIGGER’ TRIAL OF PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology. 24(Supplement_7). vii82–vii82. 1 indexed citations
12.
Liu, Rong, Neil Billington, Yi Yang, et al.. (2021). A binding protein regulates myosin-7a dimerization and actin bundle assembly. Nature Communications. 12(1). 563–563. 16 indexed citations
13.
Liu, Rong, Yi Yang, Amy Hong, et al.. (2018). The Enzymatic Activity and Cellular Localization of Drosophila Myosin 7a is Regulated by a Novel Binding Protein. Biophysical Journal. 114(3). 210a–211a. 1 indexed citations
14.
Zheng, Wei, Yicong Wu, Peter W. Winter, et al.. (2017). Adaptive optics improves multiphoton super-resolution imaging. Nature Methods. 14(9). 869–872. 84 indexed citations
15.
Ingaramo, Maria, Andrew G. York, Peter Wawrzusin, et al.. (2014). Two-photon excitation improves multifocal structured illumination microscopy in thick scattering tissue. Proceedings of the National Academy of Sciences. 111(14). 5254–5259. 103 indexed citations
16.
Hong, Amy. (2014). Advocacy strategies to defend France'ssans-papiers: contradictions and complexities. The International Journal of Human Rights. 18(1). 20–44. 1 indexed citations
17.
Hong, Amy, Karine Narbonne-Reveau, Juan R. Riesgo‐Escovar, et al.. (2007). The cyclin‐dependent kinase inhibitor Dacapo promotes replication licensing during Drosophila endocycles. The EMBO Journal. 26(8). 2071–2082. 44 indexed citations
18.
Morris, Jason Z, Amy Hong, Mary A. Lilly, & Ruth Lehmann. (2005). twin, aCCR4homolog, regulates cyclin poly(A) tail length to permitDrosophilaoogenesis. Development. 132(6). 1165–1174. 69 indexed citations
19.
Hong, Amy, et al.. (2003). The p27cip/kip orthologdacapomaintains theDrosophilaoocyte in prophase of meiosis I. Development. 130(7). 1235–1242. 64 indexed citations
20.
Hong, Amy. (1999). Comparative investigation on spindle behavior and MPF activity changes during oocyte maturation between gynogenetic and amphimictic crucian carp. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Regan P. Moore Breakdown of academic impact, for papers by Cori K. Cahoon Breakdown of academic impact, for papers by Sara Cuylen‐Haering Breakdown of academic impact, for papers by Joseph Huff Breakdown of academic impact, for papers by Anand Pratap Singh Breakdown of academic impact, for papers by Jenna R. Christensen Breakdown of academic impact, for papers by Gustavo de Medeiros Breakdown of academic impact, for papers by Jeroen Vangindertael Breakdown of academic impact, for papers by Thorge Holm Breakdown of academic impact, for papers by Julian A. Eskin
Rankless by CCL
2026